Lennox-Gastaut Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Lennox-Gastaut Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that starts in early childhood, usually before the age of 4 years. It is characterized by multiple and concurrent seizure types, cognitive dysfunction, and abnormal brain electric activity. The seizures are frequent, occurring daily, and difficult to treat with anti-seizure medications. The most common seizure type is tonic seizure, which causes sudden stiffening of the body and often leads to falls and injuries. LGS can be caused by various conditions that affect the brain, such as brain malformations, infections, head trauma, or genetic disorders. However, in about 30% of cases, no cause can be found. LGS has a poor prognosis and often persists into adulthood. Treatment options include a combination of seizure medications, dietary therapy, vagus nerve stimulation, and epilepsy surgery. The goal of treatment is to improve seizure control and quality of life for people with LGS.
The Lennox-Gastaut Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Lennox-Gastaut Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lennox-Gastaut Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Lennox-Gastaut Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 28 molecules, with 27 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Lennox-Gastaut Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Lennox-Gastaut Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Lennox-Gastaut Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Azurity Pharmaceuticals IncBio-Pharm Solutions Co Ltd
BioNxt Solutions Inc.
CuroNZ Ltd
EpyGenix Therapeutics Inc
Jazz Pharmaceuticals Plc
Johns Hopkins University
Longboard Pharmaceuticals Inc
Marinus Pharmaceuticals Inc
Otsuka Pharmaceutical Co Ltd
Sentynl Therapeutics Inc
SK Life Science Inc
Sumitomo Pharma Co Ltd
Supernus Pharmaceuticals Inc
Taho Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
UCB SA
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Lennox-Gastaut Syndrome reports